aldosterone has been researched along with Angiitis in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "More than 80% of patients with type 2 diabetes mellitus develop hypertension, and approx." | 2.44 | Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. ( Savoia, C; Schiffrin, EL, 2007) |
| "Anti-aldosterone drugs have been clinically reported to be useful for their organ-protecting effects." | 2.42 | Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. ( Saruta, T; Sato, A, 2004) |
| "Type I familial hyperaldosteronism is caused by the presence of a chimaeric gene CYPl 1B1/CYP11BZ which encodes an enzyme with aldosterone synthetase activity regulated by adrenocorticotrophic hormone (ACTH)." | 1.35 | [Subclinical endothelial inflammation markers in a family with type I familial hyperaldosteronism caused by a de novo mutation]. ( Alcaíno, H; Carvajal, CA; Cattani, A; Fardella, CE; Lacourt, P; Lavandera, S; Mellado, R; Mosso, LM; Stehr, CB, 2008) |
| "Thus aldosterone and salt treatment in uninephrectomized rats led to severe hypertension and the development of a vascular inflammatory phenotype in the heart, which may represent one mechanism by which aldosterone contributes to myocardial disease." | 1.31 | Aldosterone induces a vascular inflammatory phenotype in the rat heart. ( Blomme, EA; Delyani, JA; Frierdich, GE; Kekec, BK; McMahon, EG; Nachowiak, DA; Rocha, R; Rudolph, AE, 2002) |
| "Hyperkalemia has been noted to occur spontaneously in patients with long-standing systemic lupus erythematosus who did not have advanced renal insufficiency." | 1.27 | Systemic lupus erythematosus presenting with hyporeninemic hypoaldosteronism in a 10-year-old girl. ( Bansal, VK; Fresco, R; Hano, JE; Hurley, RM; Kozeny, GA; Vertuno, LL, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marchesi, C | 1 |
| Paradis, P | 2 |
| Schiffrin, EL | 4 |
| Stehr, CB | 1 |
| Carvajal, CA | 1 |
| Lacourt, P | 1 |
| Alcaíno, H | 1 |
| Mellado, R | 1 |
| Cattani, A | 1 |
| Mosso, LM | 1 |
| Lavandera, S | 1 |
| Fardella, CE | 1 |
| Zia, AA | 1 |
| Kamalov, G | 1 |
| Newman, KP | 1 |
| McGee, JE | 1 |
| Bhattacharya, SK | 1 |
| Ahokas, RA | 1 |
| Sun, Y | 1 |
| Gerling, IC | 1 |
| Weber, KT | 1 |
| Kasal, DA | 1 |
| Barhoumi, T | 1 |
| Li, MW | 1 |
| Yamamoto, N | 1 |
| Zdanovich, E | 1 |
| Rehman, A | 1 |
| Neves, MF | 1 |
| Laurant, P | 1 |
| Briet, M | 1 |
| Rocha, R | 2 |
| Rudolph, AE | 1 |
| Frierdich, GE | 1 |
| Nachowiak, DA | 1 |
| Kekec, BK | 1 |
| Blomme, EA | 1 |
| McMahon, EG | 1 |
| Delyani, JA | 1 |
| Martin-Berger, CL | 1 |
| Yang, P | 1 |
| Scherrer, R | 1 |
| Delyani, J | 1 |
| McMahon, E | 1 |
| Funder, JW | 1 |
| Sato, A | 1 |
| Saruta, T | 1 |
| Sanz-Rosa, D | 1 |
| Cediel, E | 1 |
| de las Heras, N | 1 |
| Miana, M | 1 |
| Balfagón, G | 1 |
| Lahera, V | 1 |
| Cachofeiro, V | 1 |
| Nagata, K | 1 |
| Obata, K | 1 |
| Xu, J | 1 |
| Ichihara, S | 1 |
| Noda, A | 1 |
| Kimata, H | 1 |
| Kato, T | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Savoia, C | 1 |
| Blanner, PM | 1 |
| Barve, RA | 1 |
| Bolten, CW | 1 |
| Brown, NJ | 1 |
| Kozeny, GA | 1 |
| Hurley, RM | 1 |
| Fresco, R | 1 |
| Vertuno, LL | 1 |
| Bansal, VK | 1 |
| Hano, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for aldosterone and Angiitis
| Article | Year |
|---|---|
Role of the renin-angiotensin system in vascular inflammation.
Topics: Aldosterone; Angiotensin II; Animals; Capillary Permeability; Chemokine CCL2; Humans; Hypertension; | 2008 |
From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation.
Topics: Aldosterone; Animals; Calcium; Coronary Vessels; Disease Models, Animal; Hyperaldosteronism; Myocard | 2010 |
Vascular actions of aldosterone.
Topics: Adipocytes; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Vessels; Cardiovasc | 2013 |
Aldosterone, mineralocorticoid receptors and vascular inflammation.
Topics: Aldosterone; Animals; Glucocorticoids; Humans; Mineralocorticoid Receptor Antagonists; Mineralocorti | 2004 |
Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Humans; Mice; Mice, Transgenic; Re | 2004 |
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.
Topics: Aldosterone; Angiotensin II; Cell Adhesion Molecules; Cytokines; Diabetes Complications; Diabetes Me | 2007 |
Aldosterone and vascular inflammation.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Vessels; Cardiovascular Diseases; Humans; Inflammation; | 2008 |
8 other studies available for aldosterone and Angiitis
| Article | Year |
|---|---|
[Subclinical endothelial inflammation markers in a family with type I familial hyperaldosteronism caused by a de novo mutation].
Topics: Adolescent; Aldosterone; Biomarkers; C-Reactive Protein; Cytochrome P-450 CYP11B2; Endothelium, Vasc | 2008 |
T regulatory lymphocytes prevent aldosterone-induced vascular injury.
Topics: Adaptive Immunity; Adoptive Transfer; Aldosterone; Animals; Endothelium, Vascular; Hypertension; Imm | 2012 |
Aldosterone induces a vascular inflammatory phenotype in the rat heart.
Topics: Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Coronary Vessels; Cyclooxygenase 2; Endomyocar | 2002 |
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Body Weight; Coronary Disease; Coronary Vessels | 2002 |
Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system.
Topics: Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combination; Eplerenone; Hypertension; | 2005 |
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Coronary Vessels; Corti | 2006 |
Mineralocorticoid receptors and vascular inflammation: new answers, new questions.
Topics: Aldosterone; Animals; Gene Expression Regulation; Models, Animal; Models, Biological; Receptors, Min | 2007 |
Systemic lupus erythematosus presenting with hyporeninemic hypoaldosteronism in a 10-year-old girl.
Topics: Aldosterone; Child; Female; Humans; Hyperkalemia; Lupus Erythematosus, Systemic; Lupus Nephritis; Re | 1986 |